Wedbush ups SpringWorks target to $81, expects Merck KGaA ‘official' offer soon [Yahoo! Finance]
Germany's Merck In Talks To Buy Cancer Drug Maker SpringWorks Therapeutics [Yahoo! Finance]
InnovationRx: Federal Judges Halt Trump’s Cuts To NIH Research Payments [Forbes]
SpringWorks Therapeutics, Inc. (NASDAQ: SWTX) had its price target raised by analysts at Evercore ISI from $60.00 to $65.00. They now have an "outperform" rating on the stock.
SpringWorks Therapeutics, Inc. (NASDAQ: SWTX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $74.00 price target on the stock.